Lupin Ltd has received a Form 483 with three observations from the US Food and Drug Administration following an inspection of its Somerset, New Jersey manufacturing facility. Conducted between April 13 and April 17, 2026, the inspection underscores the stringent regulatory oversight faced by pharmaceutical companies operating in the United States. While the observations do not immediately imply regulatory action, they require timely corrective measures.